Drug Trial Radar · NCT07807007
Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Nov 21, 2025
Primary completion
Aug 3, 2026
Study completion Aug 17, 2026
Sponsor
- Lead sponsor
- Shanghai Xin Huanghe Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether two different doses of an investigational drug (CP006 Inhalation Powder, a triple combination of budesonide, formoterol, and umeclidinium) improve lung function in adults with asthma compared to an active comparator (budesonide/formoterol inhalation powder, a marketed two-component product). The main questions it aims to answer are: Does CP006 produce a greater change in lung function (measured by trough FEV₁ before morning dose) after 28 days of treatment compared to the comparator? What medical problems do participants experience when taking CP006? Researchers will compare two dose levels of CP006 against the active comparator in a 1:1:1 ratio. Participants will: Complete a screening visit (up to 7 days) to confirm eligibility, including medical history, physical exam, and lung function tests Enter a 14-day run-in period during which they take the comparator medication (budesonide/formoterol) twice daily Be randomly assigned to one of three treatment groups: CP006 Dose 1, CP006 Dose 2, or the comparator Take their assigned treatment twice daily for 28 days Visit the clinic at Day 0 (baseline), Day 8, Day 15, and Day 29 for lung function tests, safety checks, and questionnaires (ACQ-5 and AQLQ) Measure their morning and evening peak expiratory flow (PEF) daily using a handheld device and record the results in a diary Return for a follow-up safety visit or phone call at Day 43 (±2 days) The total duration of participation is approximately 58 to 65 days.
Conditions
- Asthma
Interventions
Budesonide, Formoterol Fumarate, and Umeclidinium BromideDrug
CP006 Inhalation Powder, 195 μg/5.5 μg/27.5 μg per inhalation. Administered as 1 inhalation twice daily for 28 days. Contains budesonide 195 μg, formoterol fumarate 5.5 μg, and umeclidinium bromide (equivalent to umeclidinium 27.5 μg) per inhalation.
Budesonide, Formoterol Fumarate, and Umeclidinium BromideDrug
CP006 Inhalation Powder, 195 μg/5.5 μg/13.8 μg per inhalation. Administered as 1 inhalation twice daily for 28 days. Contains budesonide 195 μg, formoterol fumarate 5.5 μg, and umeclidinium bromide (equivalent to umeclidinium 13.8 μg) per inhalation.
Budesonide and Formoterol FumarateDrug
Budesonide and formoterol fumarate inhalation powder (Symbicort® Turbuhaler®), 160 μg/4.5 μg per inhalation. Administered as 2 inhalations twice daily for 28 days.
Placebo for CP006 Inhalation PowderDrug
Placebo matching CP006 Inhalation Powder. Contains no active pharmaceutical ingredients. Administered as 1 inhalation twice daily for 28 days to maintain blinding.
Placebo for Budesonide and Formoterol FumarateDrug
Placebo matching budesonide and formoterol fumarate inhalation powder (Symbicort® Turbuhaler®). Contains no active pharmaceutical ingredients. Administered as 2 inhalations twice daily for 28 days to maintain blinding.
Albuterol SulfateDrug
Albuterol sulfate inhalation aerosol (Ventolin®), 100 μg per actuation. Used as rescue medication on an as-needed basis for asthma symptoms during the run-in and treatment periods.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Morning Pre-dose Trough FEV₁ at Day 29Time frame: Baseline (Day 0) and Day 29
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Hefei First People's Hospital
Hefei, Anhui, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Chongqing Fuling Central Hospital
Chongqing, Chongqing Municipality, China
Gansu Provincial Hospital
Lanzhou, Gansu, China
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Huai'an First People's Hospital
Huai'an, Jiangsu, China
Lianyungang First People's Hospital
Lianyungang, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Yan'an University Xianyang Hospital
Xianyang, Shaanxi, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Zhongjiang People's Hospital
Kaijiang, Sichuan, China
Mianyang Central Hospital
Mianyang, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.